The reality of using primaquine
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Primaquine is currently the only medication used for radical cure of Plasmodium vivax infection. Unfortunately, its use is not without risk. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency have an increased susceptibility to haemolysis when given primaquine. This potentially fatal clinical syndrome can be avoided if patients are tested for G6PD deficiency and adequately informed before being treated. CASE PRESENTATION: A 35-year old male presented to our clinic on the Thai-Burmese border with a history and clinical examination consistent with intravascular haemolysis. The patient had been prescribed primaquine and chloroquine four days earlier for a P. vivax infection. The medication instructions had not been given in a language understood by the patient and he had not been tested for G6PD deficiency. The patient was not only G6PD deficient but misunderstood the instructions and took all his primaquine tablets together. With appropriate treatment the patient recovered and was discharged home a week later. CONCLUSIONS: Whilst primaquine remains the drug of choice to eradicate hypnozoites and control P. vivax transmission, the risks associated with its use must be minimized during its deployment. In areas where P. vivax exists, patients should be tested for G6PD deficiency and adequately informed before administration of primaquine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Low seroprevalence of HIV and syphilis in pregnant women in refugee camps on the Thai-Burma border.
Plewes, K., Lee, T., Kajeechewa, L., Thwin, M. M., Lee, S. J., Carrara, V. I., Nosten, F., & Mcgready, R. (2008) · International Journal of STD & AIDS · doi:10.1258/ijsa.2008.008034 · Cited by 66
Self-citation
Cited by
Howes, R. E., Piel, F. B., Patil, A. P., Nyangiri, O. A., Gething, P. W., Dewi, M., Hogg, M. M., Battle, K. E., Padilla, C. D., Baird, J. K., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001339 · Cited by 562
Evidence and Implications of Mortality Associated with Acute Plasmodium vivax Malaria
Baird, J. K. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-12 · Cited by 398
“Diagnosis of G6PDd requires a laboratory capacity that is largely absent in areas where most malaria patients live, and inadvertent dosing of G6PDd patients with primaquine can lead to serious hemolytic anemia and even death (19, 20).”
BackgroundAdaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery
Marques, J., Valle-Delgado, J. J., Urbán, P., Baró, E., Prohens, R., Mayor, A., Cisteró, P., Delves, M., Sinden, R. E., Grandfils, C., et al. (2017) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.09.010 · Cited by 64
“In patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency PQ generally induces RBC oxidative damage that eventually results in hemolytic anemia which may be severe.(33,34) Such toxicological concerns have led to restrictions in the use of this drug since the incidence of G6PD genetic anomaly is particularly…”
BackgroundUrban, P., & Fernandez-Busquets, X. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113206660292 · Cited by 39
Metadata
- Authors
- Burgoine, K. L., Bancone, G., & Nosten, F.
- Venue
- Malaria Journal
- Published
- 2010-12
- Volume
- 9
- Issue
- 1
- Pages
- 376-376
- ISSN
- 1475-2875 (ISSN-L)
- OpenAlex
- W2107159719
- Cited by
- 44
- References
- 1
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.